Breakthrough T1D has removed the previous $3 million funding cap, allowing you to request an award size and duration tailored to your specific project scope. Additionally, the schedule has shifted to a fully rolling basis, meaning both Letters of Intent and full proposals are now accepted year-round without fixed deadlines.
Funder: Breakthrough T1D
Due Dates: Rolling (LOIs and proposals accepted year-round; contact funder before submission)
Funding Amounts: No explicit cap; award size and duration are as approved, typically require 1:1 company matching funds; indirect costs not permitted.
Summary: Supports for-profit entities conducting research and development of therapeutics or devices for type 1 diabetes with commercial potential, aligned with Breakthrough T1D’s research priorities.
Key Information: Applicants must commit matching funds equal to or greater than the requested amount; pre-LOI discussion with funder required.